重型颅脑创伤后抗凝血酶缺乏与抗心磷脂抗体的发生率:前瞻性队列研究
该前瞻性队列研究纳入40例需颅内压监测的重型颅脑创伤患者(85%男性,中位年龄42岁),在入院时、第1天及第5至7天系列检测抗心磷脂抗体、抗凝血酶水平、血栓弹力图及凝血参数。7例(18%)出现IgG或IgM抗心磷脂抗体滴度升高;15例(38%)抗凝血酶水平低于正常,尤其在第0天和第1天;14例(38%)血栓弹力图最大血凝块强度增高并伴纤维蛋白原浓度和血小板计数升高。4例(10%)发生深静脉血栓,10例(25%)死亡,两者均与抗心磷脂抗体存在无显著相关(P=0.619和P=0.638)。作者认为抗心磷脂抗体与颅脑创伤严重程度或临床血栓栓塞事件的定量关系值得进一步研究。
要点
- 重型颅脑创伤需颅内压监测患者中,18%(7/40)出现IgG或IgM抗心磷脂抗体滴度升高。
- 38%(15/40)抗凝血酶水平低于正常,尤其在第0天和第1天。
- 38%(14/40)血栓弹力图最大血凝块强度增高,伴纤维蛋白原浓度和血小板计数升高。
- 10%(4/40)发生深静脉血栓,25%(10/40)死亡,均与抗心磷脂抗体存在无显著相关(P=0.619和P=0.638)。
适用人群与场景
- 需颅内压监测的重型颅脑创伤患者,共40例,85%男性,中位年龄42岁。
研究设计与关键结果
- 前瞻性队列研究,纳入40例需颅内压监测的重型颅脑创伤患者,在入院时、第1天及第5至7天系列检测抗心磷脂抗体、抗凝血酶、血栓弹力图及凝血参数。
- 7例(18%)出现IgG或IgM抗心磷脂抗体滴度升高。
- 15例(38%)抗凝血酶水平低于正常,尤其在第0天和第1天。
- 14例(38%)血栓弹力图最大血凝块强度增高,伴纤维蛋白原浓度和血小板计数升高。
- 4例(10%)发生深静脉血栓,10例(25%)死亡,均与抗心磷脂抗体存在无显著相关(P=0.619和P=0.638)。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性;作者在结论中提出抗心磷脂抗体与颅脑创伤严重程度或临床血栓栓塞事件的定量关系值得进一步研究。
对床旁实践的改变
- 作者认为,重型颅脑创伤后抗凝血酶降低和抗心磷脂抗体出现并不少见,随后可因纤维蛋白原浓度和血小板计数升高而出现体外血凝块强度增高;抗心磷脂抗体与颅脑创伤严重程度或临床血栓栓塞事件的定量关系值得进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Animal studies suggested that cerebral mitochondrial cardiolipin phospholipids were released after severe traumatic brain injury (TBI), contributing to the pathogenesis of thromboembolism.
OBJECTIVES: To determine the incidence of anti-cardiolipin antibodies after severe TBI and whether this was related to the severity of TBI and development of venous thromboembolism.
METHODS: Serial anti-cardiolipin antibodies, antithrombin levels, viscoelastic testing, and coagulation parameters were measured on admission, day-1, and between day-5 and day-7 in patients with severe TBI requiring intracranial pressure monitoring.
RESULTS: Of the 40 patients included (85% male and median age 42 years), 7 (18%) had a raised Ig-G or Ig-M anti-cardiolipin antibody titer after TBI. Antithrombin levels were below the normal level-especially on day-0 and day-1-in 15 patients (38%), and 14 patients (38%) developed an increase in maximum clot firmness on the viscoelastic test in conjunction with elevations in fibrinogen concentration and platelet count. Four patients (10%) developed deep vein thrombosis, and 10 patients (25%) died, both of which were not significantly related to the presence of anti-cardiolipin antibodies (P = 0.619 and P = 0.638, respectively).
CONCLUSIONS: A reduction in antithrombin level and development of anti-cardiolipin antibodies were not rare immediately after severe TBI; these abnormalities were followed by an increase in in vitro clot strength due to elevations in fibrinogen concentration and platelet count. The quantitative relationships between the development of anti-cardiolipin antibodies and severity of TBI or clinical thromboembolic events deserve further investigation.
参考来源
- Kalgudi S, Ho KM. Incidence of Antithrombin Deficiency and Anti-Cardiolipin Antibodies After Severe Traumatic Brain Injury: A Prospective Cohort Study. Neurocrit Care. 2021. PMID: 32557110. doi:10.1007/s12028-020-01026-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。